Challenges for the formulation of a universal vaccine against dengue

Experimental Biology and Medicine

Volumn 238, Issue 5, 2013, Pages 566-578

  Chokephaibulkit, Kulkanya ^a   Perng, Guey Chuen ^b,c,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dengue fever; Dengue vaccine; DHF; Flavivirus

Indexed keywords

DENGUE VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY;

DENGUE; DENGUE VIRUS; DISEASE COURSE; DRUG EFFICACY; DRUG FORMULATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; LABORATORY DIAGNOSIS; NONHUMAN; REVIEW; SEROTYPE; VACCINATION; VIREMIA; VIRUS INTERFERENCE; VIRUS STRAIN; VIRUS VIRULENCE;

DENGUE FEVER; DENGUE VACCINE; DHF; FLAVIVIRUS;

AEDES; ANIMALS; COMMUNICABLE DISEASE CONTROL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS; IMMUNOLOGIC MEMORY; INSECT VECTORS;

EID: 84881606622     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.1177/1535370212473703     Document Type: Review

References (109)

1. WHO. Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. Geneva: World Health Organization, 2009
2. Tsai J-J, Liu L-T, Chang K, Wang S-H, Hsiao H-M, Clark KB, Perng GC. The importance of hematopoietic progenitor cells in dengue. Ther Adv Hematol 2012;3:59-71
3. Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, Hunsperger E, Kroeger A, Margolis HS, Martinez E, Nathan MB, Pelegrino JL, Simmons C, Yoksan S, Peeling RW. Dengue: a continuing global threat. Nat Rev Microbiol 2010;8:S7-S16
4. Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 2011;29:587-619
5. Cassetti MC, Durbin A, Harris E, Rico-Hesse R, Roehrig J, Rothman A, Whitehead S, Natarajan R, Laughlin C. Report of an NIAID workshop on dengue animal models. Vaccine 2010;28:4229-4234
6. Sabin AB, Schlesinger RW. Production of immunity to dengue with virus modified by propagation in mice. Science 1945;101:640-642
7. Kimura Ra SH. Studies on dengue fever (VI). On the inoculation of dengue virus into mice (in Japanese). Nippom Igaku 1944:629-633
8. WHO. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Geneva: World Health Organization, 1997:84
9. Sabin AB. Research on dengue duringWorldWar II. Am J Trop Med Hyg 1952;1:30-50
10. Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science 1988;239:476-481
11. WHO. Guide for diagnosis, treatment and control of dengue hemorrhagic fever, 1980. Available at: http://www.who.int/csr/resources/publications/dengue/Denguepublication/en/
12. Gusman MG. Dengue vaccines: new developments. Drugs Future 2011;36:45-62
13. Thomas SJ, Endy TP. Vaccines for the prevention of dengue: development update. Hum Vaccine 2011;7:674-684
14. Schmitz J, Roehrig J, Barrett A, Hombach J. Next generation dengue vaccines: a review of candidates in preclinical development. Vaccine 2011;29:7276-7284
15. Perng GC, Lei HY, Lin YS, Choekphaibulkit K. Dengue vaccines: challenge and confrotation. World J Vaccines 2011;1:109-130
16. Edelman R. Unique challenges faced by the clinical evaluation of dengue vaccines. Expert Rev Vaccines 2011;10:133-136
17. Danko JR, Beckett CG, Porter KR. Development of dengue DNA vaccines. Vaccine 2011
18. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant subunit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011
19. Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Pat 2010;20:819-835
20. WHO. Dengue Vaccine Development: The Role of the WHO South-East Asia Regional Office, 2010
21. Wilder-Smith A, Ooi EE, Vasudevan SG, Gubler DJ. Update on dengue: epidemiology, virus evolution, antiviral drugs, and vaccine development. Curr Infect Dis Rep 2010;12:157-164
22. Clark DV, Mammen MP Jr, Nisalak A, Puthimethee V, Endy TP. Economic impact of dengue fever/dengue hemorrhagic fever in Thailand at the family and population levels. Am J Trop Med Hyg 2005;72:786-791
23. Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 2002;10:100-103
24. WHO. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever. Revised and expanded edition. SEARO Technical Publication Series, 2011:60. Available at: http://www.searo.who.int/LinkFiles/Dengue_DHF_prevention&control_guidelines_rev.pdf.
25. Barniol J, Gaczkowski R, Barbato EV, da Cunha RV, Salgado D, Martinez E, Segarra CS, Pleites Sandoval EB, Mishra A, Laksono IS, Lum LC, Martinez JG, Nunez A, Balsameda A, Allende I, Ramirez G, Dimaano E, Thomacheck K, Akbar NA, Ooi EE, Villegas E, Hien TT, Farrar J, Horstick O, Kroeger A, Jaenisch T. Usefulness and applicability of the revised dengue case classification by disease: multi-centre study in 18 countries. BMC Infect Dis 2011;11:106
26. Basuki PS, Budiyanto, Puspitasari D, Husada D, Darmowandowo W, Ismoedijanto Soegijanto Yamanaka SA. Application of revised dengue classification criteria as a severity marker of dengue viral infection in Indonesia. Southeast Asian J Trop Med Public Health 2010;41:1088-1094
27. Peeling RW, Artsob H, Pelegrino JL, Buchy P, Cardosa MJ, Devi S, Enria DA, Farrar J, Gubler DJ, Guzman MG, Halstead SB, Hunsperger E, Kliks S, Margolis HS, Nathanson CM, Nguyen VC, Rizzo N, Vazquez S, Yoksan S. Evaluation of diagnostic tests: dengue. Nat Rev Microbiol 2010;8:S30-S38
28. Bargeron Clark K, Hsiao HM, Noisakran S, Tsai JJ, Perng GC. Role of microparticles in dengue virus infection and its impact on medical intervention strategies. Yale J Biol Med 2012; 85:3-18
29. Ardati N. Observation on dengue. Med Rec 1910;78:408-409
30. Onlamoon N, Noisakran S, Hsiao HM, Duncan A, Villinger F, Ansari AA, Perng GC. Dengue virus-induced hemorrhage in a nonhuman primate model. Blood 2010;115:1823-1834
31. Tsai JJ, Jen YH, Chang JS, Hsiao HM, Noisakran S, Perng GC. Frequency alterations in key innate immune cell components in the peripheral blood of dengue patients detected by FACS analysis. J Innate Immun 2011;3:530-540
32. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 2002;108:717-725
33. Junjhon J, Lausumpao M, Supasa S, Noisakran S, Songjaeng A, Saraithong P, Chaichoun K, Utaipat U, Keelapang P, Kanjanahaluethai A, Puttikhunt C, Kasinrerk W, Malasit P, Sittisombut N. Differential modulation of prM cleavage, extracellular particle distribution, and virus infectivity by conserved residues at nonfurin consensus positions of the dengue virus pr-M junction. J Virol 2008;82:10776-10791
34. Sabin AB. Electron microscope studies on human dengue serum. Am J Publ Health 1951;41:1215
35. de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, de Silva AM. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA 2012;109:7439-7444
36. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E. Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 2012;429:12-20
37. Midgley CM, Bajwa-Joseph M, Vasanawathana S, Limpitikul W, Wills B, Flanagan A, Waiyaiya E, Tran HB, Cowper AE, Chotiyarnwong P, Grimes JM, Yoksan S, Malasit P, Simmons CP, Mongkolsapaya J, Screaton GR. An in-depth analysis of original antigenic sin in dengue virus infection. J Virol 2011;85:410-421
38. Kurane I, Kontny U, Janus J, Ennis FA. Dengue-2 virus infection of human mononuclear cell lines and establishment of persistent infections. Arch Virol 1990;110:91-101
39. Noisakran S, Perng GC. Alternate hypothesis on the pathogenesis of dengue hemorrhagic fever (DHF)/dengue shock syndrome (DSS) in dengue virus infection. Exp Biol Med (Maywood) 2008;233:401-408
40. Rothman AL. Immunity to dengue virus: a tale of original antigenic sin and tropical cytokine storms. Nat Rev Immunol 2011;11:532-543
41. Noisakran S, Onlamoon N, Songprakhon P, Hsiao HM, Chokephaibulkit K, Perng GC. Cells in dengue virus infection in vivo. Adv Virol 2010;2010:164878. doi: 10.1155/2010/164878
42. Williams K, Burdo TH. Monocyte mobilization, activation markers, and unique macrophage populations in the brain: observations from SIV infected monkeys are informative with regard to pathogenic mechanisms of HIV infection in humans. J Neuroimmune Pharmacol 2012;7:363-371
43. Gras G, Kaul M. Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 2010;7:30
44. Suthar MS, Ma DY, Thomas S, Lund JM, Zhang N, Daffis S, Rudensky AY, Bevan MJ, Clark EA, Kaja MK, Diamond MS, Gale M Jr. IPS-1 is essential for the control of West Nile virus infection and immunity. PLoS Pathog 2010;6:e1000757
45. Town T, Bai F, Wang T, Kaplan AT, Qian F, Montgomery RR, Anderson JF, Flavell RA, Fikrig E. Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing. Immunity 2009;30:242-253
46. Nazmi A, Dutta K, Das S, Basu A. Japanese encephalitis virus-infected macrophages induce neuronal death. J Neuroimmune Pharmacol 2011;6:420-433
47. Noisakran S, Gibbons RV, Songprakhon P, Jairungsri A, Ajariyakhajorn C, Nisalak A, Jarman RG, Malasit P, Chokephaibulkit K, Perng GC. Detection of dengue virus in platelets isolated from dengue patients. Southeast Asian J Trop Med Public Health 2009;40:253-262
48. Bierman HR, Nelson ER. Hematodepressive virus diseases of Thailand. Ann Intern Med 1965;62:867-884
49. Noisakran S, Onlamoon N, Hsiao HM, Clark KB, Villinger F, Ansari AA, Perng GC. Infection of bone marrow cells by dengue virus in vivo. Exp Hematol 2012;40:250-259+e254
50. Nakao S, Lai CJ, Young NS. Dengue virus, a flavivirus, propagates in human bone marrow progenitors and hematopoietic cell lines. Blood 1989;74:1235-1240
51. Young NS. Flaviviruses and bone marrow failure. JAMA 1990;263:3065-3068
52. Pang T. Studies into the immunopathogenesis and laboratory diagnosis of dengue haemorrhagic fever. Ann Acad Med Singapore 1987;16:612-616
53. Mathew A, Kurane I, Green S, Vaughn DW, Kalayanarooj S, Suntayakorn S, Ennis FA, Rothman AL. Impaired T cell proliferation in acute dengue infection. J Immunol 1999;162:5609-5615
54. Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998;11:480-496
55. Rico-Hesse R. Microevolution and virulence of dengue viruses. Adv Virus Res 2003;59:315-341
56. Thant KZ, Morita K, Igarashi A. Detection of the disease severity-related molecular differences among new Thai dengue-2 isolates in 1993, based on their structural proteins and major non-structural protein NS1 sequences. Microbiol Immunol 1996;40:205-216
57. Puri B, Nelson WM, Henchal EA, Hoke CH, Eckels KH, Dubois DR, Porter KR, Hayes CG. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J Gen Virol 1997; 78(Pt 9):2287-2291
58. Chen W, Kawano H, Men R, Clark D, Lai CJ. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J Virol 1995;69:5186-5190
59. Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 1977;265:739-741
60. Halstead SB, Venkateshan CN, Gentry MK, Larsen LK. Heterogeneity of infection enhancement of dengue 2 strains by monoclonal antibodies. J Immunol 1984;132:1529-1532
61. Kurane I, Innis BL, Nisalak A, Hoke C, Nimmannitya S, Meager A, Ennis FA. Human T cell responses to dengue virus antigens. Proliferative responses and interferon gamma production. J Clin Invest 1989;83:506-513
62. Kurane I, Rothman AL, Livingston PG, Green S, Gagnon SJ, Janus J, Innis BL, Nimmannitya S, Nisalak A, Ennis FA. Immunopathologic mechanisms of dengue hemorrhagic fever and dengue shock syndrome. Arch Virol Suppl. 1994;9:59-64
63. Chao DY, Lin TH, Hwang KP, Huang JH, Liu CC, King CC. 1998 dengue hemorrhagic fever epidemic in Taiwan. Emerg Infect Dis 2004;10:552-554
64. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, Potts JA, Jarman RG, Yoon IK, Gibbons RV, Brion JD, Capeding RZ. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med 2009;6:e1000171
65. Meltzer E, Schwartz E. A travel medicine view of dengue and dengue hemorrhagic fever. Travel Med Infect Dis 2009;7:278-283
66. Chiu YC, Wu KL, Kuo CH, Hu TH, Chou YP, Chuah SK, Kuo CM, Kee KM, Changchien CS, Liu JW, Chiu KW. Endoscopic findings and management of dengue patients with upper gastrointestinal bleeding. Am J Trop Med Hyg 2005;73:441-4
67. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 1989;11(Suppl. 4):S830-S839
68. Sandler NG, Douek DC. Microbial translocation in HIV infection: causes, consequences and treatment opportunities. Nat Rev Microbiol 2012;10:655-666
69. Swank GM, Deitch EA. Role of the gut in multiple organ failure: bacterial translocation and permeability changes. World J Surg 1996;20:411-417
70. Usawattanakul W, Nimmannitya S, Sarabenjawong K, Tharavanij S. Endotoxin and dengue haemorrhagic fever. Southeast Asian J Trop Med Public Health 1986;17:8-12
71. Vejchapipat P, Theamboonlers A, Chongsrisawat V, Poovorawan Y. An evidence of intestinal mucosal injury in dengue infection. Southeast Asian J Trop Med Public Health 2006;37:79-82
72. Meltzer E, Heyman Z, Bin H, Schwartz E. Capillary leakage in travelers with dengue infection: implications for pathogenesis. Am J Trop Med Hyg 2012;86:536-539
73. van de Weg CA, Koraka P, van Gorp EC, Mairuhu AT, Supriatna M, Soemantri A, van de Vijver DA, Osterhaus AD, Martina BE. Lipopolysaccharide levels are elevated in dengue virus infected patients and correlate with disease severity. J Clin Virol 2012;53:38-42
74. Kou Z, Lim JY, Beltramello M, Quinn M, Chen H, Liu S, Martinez-Sobrido L, Diamond MS, Schlesinger JJ, de Silva A, Sallusto F, Jin X. Human antibodies against dengue enhance dengue viral infectivity without suppressing type I interferon secretion in primary human monocytes. Virology 2011;410:240-247
75. Hotta H, Hotta S. Dengue virus multiplication in cultures of mouse peritoneal macrophages: effects of macrophage activators. Microbiol Immunol 1982;26:665-676
76. Hotta H, Hotta S, Takada H, Kotani S, Tanaka S, Ohki M. Enhancement of dengue virus type 2 replication in mouse macrophage cultures by bacterial cell walls, peptidoglycans, and a polymer of peptidoglycan subunits. Infect Immun 1983;41:462-469
77. Sakuntabhai A, Turbpaiboon C, Casademont I, Chuansumrit A, Lowhnoo T, Kajaste-Rudnitski A, Kalayanarooj SM, Tangnararatchakit K, Tangthawornchaikul N, Vasanawathana S, Chaiyaratana W, Yenchitsomanus PT, Suriyaphol P, Avirutnan P, Chokephaibulkit K, Matsuda F, Yoksan S, Jacob Y, Lathrop GM, Malasit P, Despres P, Julier C. A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet 2005;37: 507-513
78. Ashburn PMCF. Experimental investigations regarding the etiology of dengue. J Infect Dis 1907;4:440-475
79. Hotta S. Experimental studies on dengue I isolation, identification and modification of the virus. J Infect Dis 1952;90:1-9
80. Hotta S. Therapeutic experiments on dengue infection in mice. Ann Trop Med Parasitol 1953;47:1-8
81. Hotta S. Some immunological properties of dengue virus cultivated in tissue culture. Ann Trop Med Parasitol 1957;51:249-255
82. Cleland JB, Bradley B, MacdonaldW. Further eperiments in the etiology of dengue fever. J Hyg (Lond) 1919;18:217-254
83. Paul JR, Melnick JL, Sabin AB. Experimental attempts to transmit phlebotomus and dengue fevers to chimpanzees. Proc Soc Exp Biol Med 1948;68:193
84. Hammon WM, Rudnick A, Sather GE. Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science 1960;131:1102-1103
85. Thomas SJ, Endy TP. Critical issues in dengue vaccine development. Curr Opin Infect Dis 2011
86. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012
87. Halstead SB, Palumbo NE. Studies on the immunization of monkeys against dengue. II. Protection following inoculation of combinations of viruses. Am J Trop Med Hyg 1973;22:375-381
88. Halstead SB. Dengue. Lancet 2007;370:1644-1652
89. Ruechusatsawat K, Morita K, Tanaka M, Vongcheree S, Rojanasuphot S, Warachit P W, Kanai K, Thongtradol P, Kanungkid S, Igarashi A. Daily observation of antibody levels among dengue patients detected by enzyme-linked immunosorbent assay (ELISA). Jpn J Trop Med Hyg 1994;22:9-12
90. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Endy TP, Raengsakulrach B, Rothman AL, Ennis FA, Nisalak A. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000;181:2-9
91. Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP. Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infections: how alterations in assay conditions impact performance. Am J Trop Med Hyg 2009;81:825-833
92. Watanaveeradej V, Simasathien S, Nisalak A, Endy TP, Jarman RG, Innis BL, Thomas SJ, Gibbons RV, Hengprasert S, Samakoses R, Kerdpanich A, Vaughn DW, Putnak JR, Eckels KH, Barrera Rde L, Mammen MP Jr. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus-naive infants. Am J Trop Med Hyg 2011;85:341-351
93. Simasathien S, Thomas SJ, Watanaveeradej V, Nisalak A, Barberousse C, Innis BL, Sun W, Putnak JR, Eckels KH, Hutagalung Y, Gibbons RV, Zhang C, De La Barrera R, Jarman RG, Chawachalasai W, Mammen MP Jr. Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children. Am J Trop Med Hyg 2008;78:426-433
94. Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, Chen L, Hayes C, Dong JY, Porter K. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008;82:6927-6934
95. Craig S, Thu HM, Lowry K, Wang XF, Holmes EC, Aaskov J. Diverse dengue type 2 virus populations contain recombinant and both parental viruses in a single mosquito host. J Virol 2003;77:4463-4467
96. Dittmar D, Castro A, Haines H. Demonstration of interference between dengue virus types in cultured mosquito cells using monoclonal antibody probes. J Gen Virol 1982;59:273-282
97. Kitchener S, Nissen M, Nasveld P, Forrat R, Yoksan S, Lang J, Saluzzo JF. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 2006;24:1238-1241
98. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, Vaughn DW, Thomas SJ, Kanesa-Thasan N, Innis BL, Edelman R. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 2009;5:33-40
99. Guy B, Barban V, Mantel N, Aguirre M, Gulia S, Pontvianne J, Jourdier TM, Ramirez L, Gregoire V, Charnay C, Burdin N, Dumas R, Lang J. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 2009;80:302-311
100. Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Rev Panam Salud Publ 2007;21:254-260
101. Moxon ER, Siegrist CA. The next decade of vaccines: societal and scientific challenges. Lancet 2011;378:348-359
102. Sabin AB. Oral poliovirus vaccine. Recent results and recommendations for optimum use. R Soc Health J 1962;82:51-59
103. Sabin AB. Viral and Rickettsial Infections of Man. Philadelphia: J.B.Lippincott Company, 1959
104. Tasumi S, Velikovsky CA, Xu G, Gai SA, Wittrup KD, Flajnik MF, Mariuzza RA, Pancer Z. High-affinity lamprey VLRA and VLRB monoclonal antibodies. Proc Natl Acad Sci USA 2009;106: 12891-12896
105. Alder MN, Herrin BR, Sadlonova A, Stockard CR, Grizzle WE, Gartland LA, Gartland GL, Boydston JA, Turnbough CL Jr, Cooper MD. Antibody responses of variable lymphocyte receptors in the lamprey. Nat Immunol 2008;9:319-327
106. Liu JW, Jiang JQ, Zhang HT, Fang Y, An ZX. Synthesis and identification of norfloxacin artificial antigen. Adv Mater Res 2012;433-440:697-702
107. Gwinn W, Sun W, Innis BL, Caudill J, King AD. Serotype-specific T(H)1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines. Am J Trop Med Hyg 2003;69:39-47
108. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, Suntayakorn S, Rothman AL, Ennis FA, Nisalak A. Dengue in the early febrile phase: viremia and antibody responses. J Infect Dis 1997;176:322-330
109. Russell PK, Nisalak A, Sukhavachana P, Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967;99:285-290